Kevin Feeley Sells 1,137 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,137 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $76.37, for a total transaction of $86,832.69. Following the completion of the transaction, the chief financial officer now directly owns 24,731 shares of the company’s stock, valued at approximately $1,888,706.47. The trade was a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The stock was sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total transaction of $18,248.40.

GeneDx Stock Down 2.8 %

GeneDx stock opened at $71.77 on Friday. The stock has a market cap of $1.97 billion, a P/E ratio of -23.08 and a beta of 2.04. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a twelve month low of $1.66 and a twelve month high of $89.11. The company’s 50-day moving average price is $69.70 and its two-hundred day moving average price is $44.98.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company had revenue of $76.90 million for the quarter, compared to analysts’ expectations of $64.98 million. During the same period last year, the firm earned ($0.82) earnings per share. The business’s revenue for the quarter was up 44.3% on a year-over-year basis. As a group, analysts expect that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of GeneDx by 4.2% during the 1st quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock worth $6,460,000 after acquiring an additional 28,678 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of GeneDx during the 2nd quarter worth approximately $9,575,000. Calamos Advisors LLC acquired a new stake in GeneDx in the second quarter valued at approximately $1,137,000. Bank of New York Mellon Corp acquired a new stake in GeneDx in the second quarter valued at approximately $991,000. Finally, nVerses Capital LLC acquired a new stake in GeneDx in the second quarter valued at approximately $50,000. 61.72% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on WGS shares. The Goldman Sachs Group increased their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Craig Hallum increased their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, Wells Fargo & Company increased their price objective on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.